Approval · Notice of Compliance 33629 · 2024
SCEMBLIX: Notice of Compliance 33629
Issued July 12, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33629
- Date
- July 12, 2024
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph with new safety information. Update to Patient Medication Information
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SCEMBLIX | Not yet assigned | — |
Medicinal ingredients
- ASCIMINIB HYDROCHLORIDE 20 MG per TAB
- ASCIMINIB HYDROCHLORIDE 40 MG per TAB